Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix

Intratumor heterogeneity in chromosomal aberrations is believed to represent a major challenge in the treatment of cancer. The aim of our work was to assess the chromosomal heterogeneity of advanced cervical carcinomas and to distinguish aberrations that had occurred at a late stage of the disease from early events. A total of 55 biopsies, sampled from 2–4 different sites within 20 tumors, were analyzed by use of comparative genomic hybridization. Heterogeneous aberrations were identified as those present in at least 1 of the biopsies and which were not seen, nor seen as a tendency, in the others of the same tumor. The homogeneous aberrations were those seen in all biopsies of the tumor. The most frequent homogeneous aberrations were gain of 3q (65%), 20q (65%) and 5p (50%), indicating that these are early events in the development of the disease. Chromosomal heterogeneity was observed in 11 tumors. The most frequent heterogeneous aberrations were loss of 4p14–q25 (60% of 10 cases with this aberration), and gain of 2p22–pter (50% of 6 cases), 11qcen–q13 (33% of 9 cases) and 8q (27% of 11 cases), suggesting that these events promote progression at a later stage. Many of the heterogeneous regions contained genes known to influence the prognosis of cervical cancer, such as 7p (EGFR), 8q (c‐MYC), 11qcen‐q13 (CCND1) and 17q (ERBB2). Three evolution sequences for the subpopulations in the heterogeneous tumors were identified: a serial, a parallel and a mixed sequence. In 2 tumors with a serial sequence, it was indicated that the aberrations +8 and −X had occurred after the other heterogeneous aberrations and hence were the aberrations most recently formed. Our results suggest pronounced chromosomal instability in advanced cervical carcinomas. Moreover, aggressive and treatment‐resistant subpopulations may emerge at a late stage and possibly contribute to a poor prognosis of the advanced stages. © 2004 Wiley‐Liss, Inc.

[1]  C. Cox,et al.  Guidelines for the implementation of clinical DNA cytometry , 2004, Breast Cancer Research and Treatment.

[2]  David I. Smith,et al.  Preferential integration of human papillomavirus type 18 near the c-myc locus in cervical carcinoma , 2003, Oncogene.

[3]  M. Mansukhani,et al.  Genetic analysis identifies putative tumor suppressor sites at 2q35–q36.1 and 2q36.3–q37.1 involved in cervical cancer progression , 2003, Oncogene.

[4]  G. Pihan,et al.  Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. , 2003, Cancer research.

[5]  D. Spandidos,et al.  Allelic imbalance in hMLH1 or BRCA2 loci associated with response of cervical and endometrial cancer to radiotherapy. , 2002, International Journal of Molecular Medicine.

[6]  K. Hui,et al.  The relevance of oncogenes as prognostic markers in cervical cancer , 2002, International Journal of Gynecologic Cancer.

[7]  A. Asplund,et al.  Clonality Analysis of Synchronous Lesions of Cervical Carcinoma Based on X Chromosome Inactivation Polymorphism, Human Papillomavirus Type 16 Genome Mutations, and Loss of Heterozygosity , 2002, The Journal of experimental medicine.

[8]  T. Cheung,et al.  Alteration of cyclin D1 and CDK4 gene in carcinoma of uterine cervix. , 2001, Cancer letters.

[9]  A. Asplund,et al.  Analysis of Intratumoral Heterogeneity of Chromosome 3p Deletions and Genetic Evidence of Polyclonal Origin of Cervical Squamous Carcinoma , 2001, Modern Pathology.

[10]  S. Garland,et al.  Progressive genetic aberrations detected by comparative genomic hybridization in squamous cell cervical cancer , 2000, British Journal of Cancer.

[11]  A. Schäffer,et al.  Chromosome abnormalities in ovarian adenocarcinoma: III. Using breakpoint data to infer and test mathematical models for oncogenesis , 2000, Genes, chromosomes & cancer.

[12]  H. Lyng,et al.  Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  A. Wyllie,et al.  Heterogeneity studies identify a subset of sporadic colorectal cancers without evidence for chromosomal or microsatellite instability , 1999, Oncogene.

[14]  M. J. van de Vijver,et al.  Genetic alterations during the progression of squamous cell carcinomas of the uterine cervix , 1999, Genes, chromosomes & cancer.

[15]  Y. Harima,et al.  Genetic alterations on chromosome 17p associated with response to radiotherapy in bulky cervical cancer , 1999, British Journal of Cancer.

[16]  P. Lazo,et al.  The molecular genetics of cervical carcinoma , 1999, British Journal of Cancer.

[17]  A. B. Mitra,et al.  Genetic deletion and human papillomavirus infection in cervical cancer: Loss of heterozygosity sites at 3p and 5p are important genetic events , 1999, International Journal of Cancer.

[18]  E. Schröck,et al.  Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: A phenotype/genotype correlation , 1999, Genes, chromosomes & cancer.

[19]  T. Stokke,et al.  Chromosomal gains and losses in primary colorectal carcinomas detected by CGH and their associations with tumour DNA ploidy, genotypes and phenotypes , 1999, British Journal of Cancer.

[20]  M. J. van de Vijver,et al.  Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  C. Lundsteen,et al.  Comparative genomic hybridization reveals a recurrent pattern of chromosomal aberrations in severe dysplasia/carcinoma in situ of the cervix and in advanced‐stage cervical carcinoma , 1999, Genes, chromosomes & cancer.

[22]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[23]  K. Sasaki,et al.  Intratumoral cytogenetic heterogeneity detected by comparative genomic hybridization and laser scanning cytometry in human gliomas. , 1998, Cancer research.

[24]  S. Knuutila,et al.  Comparison of fluorescein isothiocyanate- and Texas red-conjugated nucleotides for direct labeling in comparative genomic hybridization. , 1998, Cytometry.

[25]  E. Schröck,et al.  Advanced‐stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q , 1997, Genes, chromosomes & cancer.

[26]  P. Lichter,et al.  Specific chromosomal imbalances in human papillomavirus-transfected cells during progression toward immortality. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Børresen-Dale,et al.  Microsatellite instability in cervical and endometrial carcinomas , 1997, International journal of cancer.

[28]  Elena Savelieva,et al.  20q gain associates with immortalization: 20q13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed human uroepithelial cells , 1997, Oncogene.

[29]  S. Kern,et al.  Simultaneous assessment of loss of heterozygosity at multiple microsatellite loci using semi-automated fluorescence-based detection: subregional mapping of chromosome 4 in cervical carcinoma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  E. Schröck,et al.  Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  L D Greller,et al.  Tumor heterogeneity and progression: conceptual foundations for modeling. , 1996, Invasion & metastasis.

[32]  A. Fyles,et al.  Prognostic factors in patients with cervix cancer treated by radiation therapy: results of a multiple regression analysis. , 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[33]  M. Durm,et al.  Intratumor variability in prognostic indicators may be the cause of conflicting estimates of patient survival and response to therapy. , 1994, Cancer research.

[34]  D. Grignon,et al.  DNA content in cervical carcinoma: a flow cytometric assessment of DNA heterogeneity. , 1994, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[35]  J Piper,et al.  Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors , 1994, Genes, chromosomes & cancer.

[36]  R. Lothe,et al.  P53 expression is associated with a high-degree of tumor DNA aneuploidy and incidence of p53 gene mutation, and is localized to the aneuploid component in colorectal carcinomas. , 1993, International journal of oncology.

[37]  K. Kinzler,et al.  The multistep nature of cancer. , 1993, Trends in genetics : TIG.

[38]  C. Cox,et al.  Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. , 1993, Cytometry.

[39]  A. Proudfoot,et al.  CANCER OF THE UTERINE CERVIX , 1957, The Ulster Medical Journal.